China Life Sciences Partner Leads Webinars on Drug and Medical Device Regulatory Reform
Life sciences partner Katherine Wang (Shanghai) led discussions for a pair of webinars hosted by Ropes & Gray on May 31 and June 1, 2017. The two sessions covered topics related to proposed reforms by the China Food and Drug Administration (CFDA) to the current drug and medical device regulatory regime.
During the first webinar, titled “New CFDA Policies to Further Reform the Drug Regulatory Regime,” Ms. Wang discussed how the CFDA’s proposed changes could affect China’s pharmaceutical industry. Her presentation covered streamlining the clinical trial approval process, allowing admission of foreign study data and enhancing the accessibility of new drugs, among other proposed reforms.
In the second webinar, titled “New CFDA Policies to Further Reform the Medical Device Regulatory Regime,” Ms. Wang discussed the reforms’ impact on China’s medical device industry, including expediting ethics committee reviews, expanding clinical study infrastructure and promoting market access for innovative products.